超低剂量利图西马布与IVIG相结合在庞病中是安全和有效的:对24名患者的单中心审查
Andrew Awad1, Jessica McClatchy1,2, Ann Ramirez1
1Dermatology Department, The Royal Melbourne Hospital, Melbourne, Australia.
The Australasian journal of dermatology
|November 26, 2025
概括
一种结合超低剂量利图西马布和静脉注射免疫球蛋白的新疗法对中度至重度的原虫是安全有效的. 这一方案对以前没有服用Rituximab的患者来说是有前途的.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 黄是一种严重的自身免疫性水泡性疾病.
- 目前的治疗方法可能会产生显著的副作用.
- 需要新的治疗策略来治疗虫的管理.
研究的目的:
- 评估联合超低剂量利图西马布和静脉注射免疫球蛋白协议的安全性和有效性.
- 为了评估中度至重度的pemphigus vulgaris患者的治疗结果.
主要方法:
- 一组24名以前没有接受过Rituximab的患者,患有中度至重度的pemphigus vulgaris被治疗.
- 该方案涉及超低剂量修复剂和静脉注射免疫球蛋白的组合.
- 对患者的结果进行了安全性和有效性的监测.
主要成果:
- 综合协议显示了有利的安全性.
- 这种治疗有效地控制了中度至重度的黄.
- 所有24名先前没有接受过Rituximab的患者都对治疗产生了积极的反应.
结论:
- 结合超低剂量利图西马布和静脉注射免疫球蛋白是一种安全有效的治疗选择.
- 这一方案为pemphigus vulgaris提供了一个有前途的治疗方法.
- 进一步的研究可能会探索长期结果和更广泛的患者群体.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...


